NasdaqCM - Nasdaq Real Time Price USD

NeoGenomics, Inc. (NEO)

Compare
14.73 -0.23 (-1.54%)
As of 3:31 PM EDT. Market Open.
Loading Chart for NEO
DELL
  • Previous Close 14.96
  • Open 15.24
  • Bid 14.68 x 100
  • Ask 14.77 x 100
  • Day's Range 14.72 - 15.24
  • 52 Week Range 11.03 - 21.22
  • Volume 295,866
  • Avg. Volume 748,963
  • Market Cap (intraday) 1.888B
  • Beta (5Y Monthly) 1.19
  • PE Ratio (TTM) --
  • EPS (TTM) -0.62
  • Earnings Date Nov 4, 2024 - Nov 8, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 20.75

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

www.neogenomics.com

2,100

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NEO

View More

Performance Overview: NEO

Trailing total returns as of 9/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NEO
8.96%
S&P 500
20.37%

1-Year Return

NEO
19.17%
S&P 500
32.37%

3-Year Return

NEO
68.57%
S&P 500
28.86%

5-Year Return

NEO
25.98%
S&P 500
92.35%

Compare To: NEO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NEO

View More

Valuation Measures

Annual
As of 9/25/2024
  • Market Cap

    1.92B

  • Enterprise Value

    2.14B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.00

  • Price/Book (mrq)

    2.09

  • Enterprise Value/Revenue

    3.40

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -12.50%

  • Return on Assets (ttm)

    -3.26%

  • Return on Equity (ttm)

    -8.39%

  • Revenue (ttm)

    628.25M

  • Net Income Avi to Common (ttm)

    -78.55M

  • Diluted EPS (ttm)

    -0.62

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    387.86M

  • Total Debt/Equity (mrq)

    66.22%

  • Levered Free Cash Flow (ttm)

    -4.23M

Research Analysis: NEO

View More

Company Insights: NEO

Research Reports: NEO

View More

People Also Watch